[Federal Register Volume 67, Number 197 (Thursday, October 10, 2002)]
[Notices]
[Page 63104]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-25716]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30DAY-01-03]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 498-1210. Send written
comments to CDC, Desk Officer, Human Resources and Housing Branch, New
Executive Office Building, Room 10235, Washington, DC 20503. Written
comments should be received within 30 days of this notice.
Proposed Project
National Hospital Discharge Survey--(OMB No. 0920-0212)--National
Center for Health Statistics (NCHS), Centers for Disease Control and
Prevention (CDC) proposed to conduct a special study to evaluate
expanding pharmaceutical data in the National Health Care Survey. This
study is a preliminary investigation of methodological procedures to
collect information on drugs for inpatients as part of the National
Hospital Discharge Survey (NHDS). The National Health Care Survey
currently collects data on drugs prescribed during patient visits to
physicians' offices and to emergency and outpatient departments through
the National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey. The purpose of this special study is to
conduct and evaluate a field test of preliminary data collection
methods using medical records as the source for abstracting names of
drugs administered to a sample of hospital inpatients. It is
anticipated that the results of this special study will provide
essential information regarding: the amount of time and medical
sophistication required for staff to find and abstract drug data in the
medical record; the cost of collecting these data as part of the NHDS;
potential problems to be anticipated in conducting a national survey
which potentially requires the participation of a large number of
hospitals; and, what the next steps should be to evaluate the
possibility of adding drug data to the NHDS. The field test for this
special study will include a sample of approximately 50 hospitals which
are not currently participating in the NHDS. Data collection will
include 20 discharges sampled from one month from each participating
hospital. The data items to be abstracted are all of the NHDS items in
addition to listing the narrative description of all drugs administered
during the sampled inpatient stay. It is anticipated that only half of
the hospitals which participate in the special study will conduct their
own abstracting (``Primary procedure'') and that contractor staff will
perform the abstracting (``Alternate procedure'') in the other 25
hospitals. The total annual burden for this data collection is 367
hours.
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden/
Form respondents responses/ response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Medical Record Abstract--Primary Procedure Hospital............ 25 20 30/60
Medical Record Abstract--Alternate Procedure Hospital.......... 25 20 1/60
Induction Form................................................. 50 1 2
Transmittal Form............................................... 50 1 10/60
----------------------------------------------------------------------------------------------------------------
Dated: October 2, 2002.
Nancy E. Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers
for Disease Control and Prevention.
[FR Doc. 02-25716 Filed 10-9-02; 8:45 am]
BILLING CODE 4163-18-P